According to Seeking Alpha data, Ginkgo Bioworks has a market capitalization of $3.12B, suggesting moderate market confidence given its pioneering role in cellular design and genetic engineering.

Source: https://seekingalpha.com/article/4658816-ginkgo-bioworks-strategic-shifts-amidst-financial-uncertainty?source=feed_all_articles

Ginkgo Bioworks Holdings, Inc. () major shareholder Barry Canton sold 151,530 shares of the company’s stock in a transaction on Tuesday, January 17th.

Source: https://www.etfdailynews.com/2023/01/21/ginkgo-bioworks-holdings-inc-nysedna-major-shareholder-sells-281845-80-in-stock/

It is too early to know whether Ginkgo is capable of doing this, or even if they are really trying, but it could be an underappreciated source of value.

Source: https://seekingalpha.com/article/4606517-ginkgo-bioworks-asset-manager-in-disguise?source=feed_all_articles

On Wednesday, October 18th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock.

Source: https://www.etfdailynews.com/2023/11/27/barry-canton-sells-37650-shares-of-ginkgo-bioworks-holdings-inc-nysedna-stock/